MetaCap

KALA BIO (KALA) vs PRF Technologies (PRFX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

KALA BIO is the larger company by market cap ($1.7 million vs $1.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KALA+651.39%PRFX-45.79%
+1015%+451%-113%
Oct 7, 20261 yearNov 20, 2026
KALA+820.38%PRFX-45.86%
+864%+384%-96%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KALA versus PRFX key metrics
MetricKALAPRFX
Share price$2.71$0.4758
Market cap$1.74M$1.66M
1-day change-10.28%-23.68%
EPS (TTM)$-321.30$-4.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$17.00K
Net income (latest FY)$-26.98M$-5.02M
Gross margin—-311.76%
Operating margin—-30129.41%
Net margin—-29541.18%
52-week high$2,865.00$7.95
52-week low$2.65$0.46
Distance from 52-week high-99.91%-94.02%
Average volume52.52K228.55K
Shares outstanding644.66K3.50M
Employees66
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About KALA BIO

KALA stock →

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About PRF Technologies

PRFX stock →

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

KALA vs PRFX FAQ

Which is bigger, KALA BIO or PRF Technologies?

KALA BIO (KALA) is larger, with a market capitalization of $1.74M compared with $1.66M for PRF Technologies (PRFX).

Are KALA BIO and PRF Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons